Annual Report

2016 – 2017 Year End Summary

I. Financial Goals:  End the year with > 60 days of cash on hand and  a net income of >/= $14,000.
Implement the Wells Fargo Investment Plan

• Revenue: $2,815,050
• Expenses: $2,691,930
• Change in Net Assets: $123,120 (Budget projected $14,012)
• Days of Cash on Hand: 132 days or $804,844

Wells Fargo Investment Account

• Established September 2016
• Initial investment $721,496
• $729,301 Account Value as of June 30, 2017

II. Clinical Trial Program

1. Accruals
   NMCCA will accrue a minimum of 400 (33/month) subjects, with a minimum of 200 (17/month) NCORP accruals (150 at UNM and 50 in the community).

   July 1, 2016 to June 30, 2017 Accruals:
   NCORP accruals for the grant year (8/1/16 – 7/31/17) = 282 accruals (183.6 credits)
   NMCCA accruals = 388 accruals (518 with UNM NCORP Accruals)

2. Average time to open trials:
   The average time to open clinical trials will be 13 weeks or less; as measured from the date NMCCA receives the protocol to the time for initial IRB approval.

Average Overall Time to Open Trials

• CWG Review: 4.6 average (Goal = 3 weeks)
• CWG/PI Form Submission: 1.1 week average
• PRMC Review: 4.2 weeks average (Goal = 2 weeks)
• IRB submission: 9.1 weeks average (Goal = 4 weeks)
• IRB approval: 4.4 weeks average (Goal = 4 weeks)

• Overall average time to IRB approval: 27.7 weeks (Goal = 13 weeks and last year 19.8 weeks)
• Open Active 14.9 weeks average (Goal = 2 weeks)
• Overall Time to Open Active: 36.7 weeks average (Goal = 15 weeks)

  Time to open Goals: Not Met